These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32886304)

  • 1. Most recent strategies targeting estrogen receptor alpha for the treatment of breast cancer.
    Kumar N; Gulati HK; Sharma A; Heer S; Jassal AK; Arora L; Kaur S; Singh A; Bhagat K; Kaur A; Singh H; Singh JV; Bedi PMS
    Mol Divers; 2021 Feb; 25(1):603-624. PubMed ID: 32886304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
    Patel HK; Bihani T
    Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs).
    Wang L; Sharma A
    ChemMedChem; 2020 Nov; 15(22):2072-2097. PubMed ID: 32916035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of leads targeting ER-α in breast cancer: An in silico exploration from natural domain.
    Ashtekar SS; Bhatia NM; Bhatia MS
    Steroids; 2018 Mar; 131():14-22. PubMed ID: 29307843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen Receptor α (ERα)-targeting Compounds and Derivatives: Recent Advances in Structural Modification and Bioactivity.
    Guo WY; Zeng SM; Deora GS; Li QS; Ruan BF
    Curr Top Med Chem; 2019; 19(15):1318-1337. PubMed ID: 31215379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
    Lu Y; Liu W
    J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational approaches of drug design for the development of selective estrogen receptor modulators (SERMs), implicated in breast cancer.
    Makar S; Saha T; Swetha R; Gutti G; Kumar A; Singh SK
    Bioorg Chem; 2020 Jan; 94():103380. PubMed ID: 31757413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
    Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
    Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
    Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
    J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen-mediated inactivation of FOXO3a by the G protein-coupled estrogen receptor GPER.
    Zekas E; Prossnitz ER
    BMC Cancer; 2015 Oct; 15():702. PubMed ID: 26470790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ; Johnston SR; Howell A
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding capacity of ER-α ligands and SERMs: comparison of the human, dog and cat.
    Toniti W; Suthiyotha N; Puchadapirom P; Jenwitheesuk E
    Asian Pac J Cancer Prev; 2011; 12(11):2875-9. PubMed ID: 22393957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-Generation ERα Inhibitors for Endocrine-Resistant ER+ Breast Cancer.
    Fanning SW; Greene GL
    Endocrinology; 2019 Apr; 160(4):759-769. PubMed ID: 30753408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present).
    Scott JS; Barlaam B
    Expert Opin Ther Pat; 2022 Feb; 32(2):131-151. PubMed ID: 34763600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of molecular and structural determinants of selective estrogen receptor downregulators.
    Fan M; Rickert EL; Chen L; Aftab SA; Nephew KP; Weatherman RV
    Breast Cancer Res Treat; 2007 May; 103(1):37-44. PubMed ID: 17033922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.
    Garner F; Shomali M; Paquin D; Lyttle CR; Hattersley G
    Anticancer Drugs; 2015 Oct; 26(9):948-56. PubMed ID: 26164151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
    Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
    Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
    [No Abstract]   [Full Text] [Related]  

  • 19. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
    Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
    Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in peptidomimetics antagonists targeting estrogen receptor α-coactivator interaction in cancer therapy.
    Qin W; Xie M; Qin X; Fang Q; Yin F; Li Z
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2827-2836. PubMed ID: 30025900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.